Jha Shiva Shankar, Jeyaraman Naveen, Jeyaraman Madhan, Ramasubramanian Swaminathan, Muthu Sathish, Santos Gabriel Silva, da Fonseca Lucas Furtado, Lana José Fábio
Department of Orthopaedics, Harishchandra Orthopaedic Research Institute, Patna 880023, Bihar, India.
Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai 600077, Tamil Nadu, India.
World J Orthop. 2025 Mar 18;16(3):102274. doi: 10.5312/wjo.v16.i3.102274.
The gut microbiome comprises a vast community of microbes inhabiting the human alimentary canal, playing a crucial role in various physiological functions. These microbes generally live in harmony with the host; however, when dysbiosis occurs, it can contribute to the pathogenesis of diseases, including osteoporosis. Osteoporosis, a systemic skeletal disease characterized by reduced bone mass and increased fracture risk, has attracted significant research attention concerning the role of gut microbes in its development. Advances in molecular biology have highlighted the influence of gut microbiota on osteoporosis through mechanisms involving immunoregulation, modulation of the gut-brain axis, and regulation of the intestinal barrier and nutrient absorption. These microbes can enhance bone mass by inhibiting osteoclast differentiation, inducing apoptosis, reducing bone resorption, and promoting osteoblast proliferation and maturation. Despite these promising findings, the therapeutic effectiveness of targeting gut microbes in osteoporosis requires further investigation. Notably, gut microbiota has been increasingly studied for their potential in early diagnosis, intervention, and as an adjunct therapy for osteoporosis, suggesting a growing utility in improving bone health. Further research is essential to fully elucidate the therapeutic potential and clinical application of gut microbiome modulation in the management of osteoporosis.
肠道微生物群由居住在人体消化道中的大量微生物群落组成,在各种生理功能中发挥着关键作用。这些微生物通常与宿主和谐共生;然而,当发生生态失调时,它可能导致包括骨质疏松症在内的疾病发病。骨质疏松症是一种以骨量减少和骨折风险增加为特征的全身性骨骼疾病,肠道微生物在其发展中的作用已引起了大量研究关注。分子生物学的进展突出了肠道微生物群通过免疫调节、肠道-脑轴调节以及肠道屏障和营养吸收调节等机制对骨质疏松症的影响。这些微生物可以通过抑制破骨细胞分化、诱导凋亡、减少骨吸收以及促进成骨细胞增殖和成熟来增加骨量。尽管有这些有前景的发现,但针对肠道微生物治疗骨质疏松症的有效性仍需进一步研究。值得注意的是,肠道微生物群在骨质疏松症的早期诊断、干预以及作为辅助治疗方面的潜力越来越受到研究,这表明其在改善骨骼健康方面的应用越来越广泛。进一步的研究对于充分阐明调节肠道微生物群在骨质疏松症管理中的治疗潜力和临床应用至关重要。